Wockhardt Limited has informed the Exchange about press release dated 16-Aug-2022 titled Wockhardt announces successful initiation of Global Phase 3 Clinical Study of its novel antibiotic WCK 5222……
| Subscribe To Our Free Newsletter |
The Most Valuable Commodity Is Information!
